Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15818367 | 0.91 | USP2 (0.49) | USP2SMN1; SMN2RECQLSCD5CYP11B2 | |
| SCHEMBL29579532 | 0.90 | USP2 (0.56) | USP2SMN1; SMN2RECQLMGLLSCD5 | |
| SCHEMBL18053621 | 0.90 | USP2 (0.59) | USP2SMN1; SMN2RECQLMGLLEPHX2 | |
| SCHEMBL1222835 | 0.89 | USP2 (0.49) | USP2SMN1; SMN2RECQLSCD5CYP11B2 | |
| SCHEMBL12654039 | 0.88 | USP2 (0.51) | USP2SMN1; SMN2RECQLSCD5EPHX2 | |
| SCHEMBL24803194 | 0.88 | USP2 (0.54) | USP2SMN1; SMN2RECQLMGLLEPHX2 | |
| SCHEMBL19320633 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2RECQLMGLLSCD5 | |
| SCHEMBL22297500 | 0.88 | USP2 (0.50) | USP2SMN1; SMN2RECQLMGLLSCD5 | |
| SCHEMBL31197156 | 0.88 | USP2 (0.53) | USP2SMN1; SMN2RECQLMGLLSCD5 | |
| SCHEMBL714947 | 0.88 | USP2 (0.53) | USP2SMN1; SMN2RECQLMGLLSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | USP2 2893/4885SMN1; SMN2 2138/4885RECQL 822/4885 |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | USP2 2893/4885SMN1; SMN2 2138/4885RECQL 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.